切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2021, Vol. 15 ›› Issue (12) : 948 -953. doi: 10.3877/cma.j.issn.1674-0785.2021.12.007

临床研究

益气除痰方联合化疗对中晚期非小细胞肺癌患者近期疗效及患者血清IL-2、TNF-α和免疫功能的影响
杨玖1, 洪梅1, 刘志远1, 朱诺1,()   
  1. 1. 210029 南京,南京市胸科医院 南京医科大学附属脑科医院放疗科
  • 收稿日期:2021-06-30 出版日期:2021-12-15
  • 通信作者: 朱诺

Yiqi Chutan recipe combined with chemotherapy for treatment of patients with advanced non-small cell lung cancer: short-term curative effect and impact on serum levels of IL-2 and TNF-α and immune function

Jiu Yang1, Mei Hong1, Zhiyuan Liu1, Nuo Zhu1,()   

  1. 1. Department of Radiotherapy, Nanjing Chest Hospital, Brain Hospital Affiliated to Nanjing Medical University, Nanjing 210029, China
  • Received:2021-06-30 Published:2021-12-15
  • Corresponding author: Nuo Zhu
引用本文:

杨玖, 洪梅, 刘志远, 朱诺. 益气除痰方联合化疗对中晚期非小细胞肺癌患者近期疗效及患者血清IL-2、TNF-α和免疫功能的影响[J/OL]. 中华临床医师杂志(电子版), 2021, 15(12): 948-953.

Jiu Yang, Mei Hong, Zhiyuan Liu, Nuo Zhu. Yiqi Chutan recipe combined with chemotherapy for treatment of patients with advanced non-small cell lung cancer: short-term curative effect and impact on serum levels of IL-2 and TNF-α and immune function[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(12): 948-953.

目的

探讨益气除痰方联合化疗对中晚期非小细胞肺癌(NSCLC)患者近期疗效及对患者血清白细胞介素-2(IL-2)、肿瘤坏死因子-α(TNF-α)和免疫功能水平的影响。

方法

选取2019年1月至2021年1月南京市胸科医院收治的中晚期NSCLC患者86例,依据随机数字表法分为观察组和对照组,各43例。对照组患者给予化疗治疗,观察组患者在化疗基础上服用益气除痰方治疗。2组患者疗程以21 d为1个周期,连续治疗2个周期。比较2组患者近期疗效和生存质量改善情况,治疗前后病灶大小、IL-2、TNF-α和免疫功能变化,及毒副反应发生情况。

结果

观察组患者总有效率高于对照组(79.07% vs 55.81%,P<0.05)。2组治疗后患者病灶较治疗前减小(P<0.05);观察组治疗后患者病灶小于对照组(P<0.05)。观察组患者生存质量提高率高于对照组(83.72% vs 60.47%,P<0.05)。2组患者治疗后血清IL-2水平较治疗前升高,而TNF-α水平较治疗前降低(P<0.05);观察组患者治疗后血清IL-2水平高于对照组,而TNF-α水平低于对照组(P<0.05)。观察组患者治疗后CD3+ T细胞、CD4+ T细胞和CD4+ T细胞/CD8+ T细胞较治疗前升高(P均<0.05),并且高于对照组(P均<0.05)。观察组患者肝肾异常、骨髓抑制、胃肠道反应、白细胞减少和乏力发生率低于对照组(P均<0.05)。

结论

益气除痰方联合化疗对中晚期NSCLC患者近期疗效良好,可提高IL-2水平和降低TNF-α水平,并且提高患者免疫功能。

Objective

To evaluate the short-term curative effect of Yiqi Chutan recipe combined with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and explore its impact on the serum levels of interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α) and immune function.

Methods

A total of 86 patients with advanced NSCLC treated at Nanjing Chest Hospital from January 2019 to January 2021 were selected and divided into either an observation group or a control group using the random number table method, with 43 cases in each group. Both groups were treated with chemotherapy, and the observation group was additionally treated with Yiqi Chutan recipe. The treatment course of the two groups was 21 days as one cycle, and the treatment lasted for two cycles. The short-term efficacy and improvement of quality of life were compared between the two groups. Lesions size, serum levels of IL-2 and TNF-α, the change of immune function, and the incidence of toxicity reaction were also compared.

Results

The total effective rate in the observation group was higher than that of the control group (79.07% vs 55.81%, P<0.05). After treatment, the lesion size was significantly smaller than that before the treatment in both groups (P<0.05), and the lesion size of the observation group was significantly smaller than that of the control group (P<0.05). The rate of quality of life improvement of the observation group was significantly better than that of the control group (83.72% vs 60.47%, P<0.05). After treatment, the level of serum IL-2 increased and the level of TNF-α decreased in both groups (P<0.05); the changes in the levels of serum IL-2 and TNF-α in the observation group were more significantly than those of the control group (P<0.05). After treatment, the CD3+ cells, CD4+ cells, and CD4+/CD8+ rate in the observation group were higher than those before treatment (P<0.05 each) as well as those of the control group (P<0.05 each). Compared with the control group, the incidence of liver and kidney abnormalities, bone marrow suppression, gastrointestinal reactions, leukopenia, and fatigue in the observation group decreased significantly (P<0.05 each).

Conclusion

Yiqi Chutan recipe combined with chemotherapy has a good short-term curative effect in patients with advanced NSCLC, and can increase the level of IL-2 and decrease the level of TNF-α, and improve the immune function of patients.

表1 2组中晚期NSCLC患者一般资料比较
表2 2组中晚期NSCLC患者近期疗效比较[例(%)]
表3 2组中晚期NSCLC患者病灶大小变化比较(cm,
xˉ
±s
表4 2组中晚期NSCLC患者生存质量比较[例(%)]
表5 2组中晚期NSCLC患者血清IL-2和TNF-α水平比较(
xˉ
±s
表6 2组中晚期NSCLC患者免疫功能比较(
xˉ
±s
表7 2组中晚期NSCLC患者毒副反应情况比较[例(%)]
1
钟秀丽, 冯岗. 老年非小细胞肺癌化疗患者p53及VEGF水平与生存状况的相关性 [J]. 中国老年学杂志, 2020, 40(15): 3183-3186.
2
张美娟. 非小细胞肺癌患者发病危险因素的Logistic回归分析 [J]. 中国卫生统计, 2020, 37(3): 462-464.
3
Jang HJ, Lee HS, Ramos D, et al. Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors [J]. J Thorac Cardiovasc Surg, 2020, 159(4): 1598-1610.
4
李冲, 吴双. 含铂类化疗方案同步放化疗治疗局部晚期非小细胞肺癌的临床疗效评价 [J]. 临床内科杂志, 2019, 36(4): 275-276.
5
张洪涛, 赵凤德, 黄思宇, 等. 吉非替尼片治疗铂类方案化疗失败的中晚期非小细胞肺癌患者的临床研究 [J]. 中国临床药理学杂志, 2020, 36(15): 2219-2221.
6
曾维予, 田雪飞, 邓哲. 清金化瘀汤治疗急性放射性肺炎的疗效及对炎症因子水平的影响 [J]. 湖南中医杂志, 2019, 35(7): 8-11.
7
中华人民共和国卫生部. 原发性肺癌诊疗规范(2011年版) [M]. 北京: 中国标准出版社, 2011: 2.
8
中华人民共和国卫生部. 中药新药临床研究指导原则 [M]. 北京: 中国医药科技出版社, 1995: 219.
9
Fitzgerald K, Simone CB. Combining immunotherapy with radiation therapy in non-small cell lung cancer [J]. Thorac Surg Clin, 2020, 30(2): 221-239.
10
钟锐, 邬麟, 王伟, 等. 含铂化疗及其联合治疗在晚期非小细胞肺癌治疗中的研究进展 [J]. 肿瘤药学, 2019, 9(6): 839-844.
11
陆宽, 张博, 窦欣, 等. MSCT在含铂双药方案全身化疗治疗非小细胞肺癌的疗效评价中的应用价值 [J]. 肿瘤药学, 2018, 8(6): 955-959.
12
李冲, 吴双. 含铂类化疗方案同步放化疗治疗局部晚期非小细胞肺癌的临床疗效评价 [J]. 临床内科杂志, 2019, 36(4): 275-276.
13
王亚飞, 季也民, 赵娇阳. 益气养阴方辅助铂类为主联合化疗方案治疗气阴两虚型晚期非小细胞肺癌临床研究 [J]. 新中医, 2020, 52(16): 100-103.
14
李华, 郭丽, 憨镔, 等. 益气养阴化瘀方治疗肺癌术后复发和转移临床研究 [J]. 新中医, 2020, 52(4): 118-121.
15
宋振民, 李慧, 强亚杰, 等. 沙参麦冬汤加减联合GP化疗治疗晚期非小细胞肺癌疗效研究 [J]. 陕西中医, 2018, 39(4): 461-463.
16
扶志敏, 邝世晏, 李炽光, 等. 非小细胞肺癌血清中IL-2、IL-6、TNF-α和IFN-γ变化与生存率相关性研究 [J]. 中国现代医生, 2019, 57(11): 32-36.
17
李少昆, 安生花, 郭凤龙, 等. 肺癌患者血清TNF-α、IL-6与凝血功能的相关性研究 [J]. 实用癌症杂志, 2018, 33(11): 1773-1776.
18
郑和平, 黄梅, 蒲廷, 等. 加减沙参麦冬汤辅助治疗肺癌患者对免疫功能及不良反应的影响 [J]. 西部医学, 2020, 32(6): 896-899, 903.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 王聪, 李云涛, 唐甜甜, 王鑫蕊, 吕鑫, 范志刚. 多基因检测对激素受体阳性、HER-2阴性乳腺癌新辅助化疗疗效预测的研究进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 292-296.
[3] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[6] 薛庆, 施赛叶, 徐雅文, 盛夏, 张芹芹. 追踪方法学联合失效模式与效应分析在膀胱灌注化疗患者中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 553-559.
[7] 张昊, 潘卫东. 胰腺癌新辅助化疗后可切除性评估现状及进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 629-633.
[8] 王军华, 王锐炫. 胰腺癌新辅助化疗现状和治疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 640-643.
[9] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[10] 石阳, 于剑锋, 曹可, 翟志伟, 叶春祥, 王振军, 韩加刚. 可扩张金属支架置入联合新辅助化疗治疗完全梗阻性左半结肠癌围手术期并发症分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 464-471.
[11] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[12] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[13] 张颖, 赵鑫, 陈佳梅, 李雁. 术前化疗对CRS+HIPEC 治疗腹膜假黏液瘤预后影响的meta 分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 826-835.
[14] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
[15] 张梦婷, 穷拉姆, 色珍, 李逸群, 德庆旺姆. 西藏地区藏族乳腺癌新辅助化疗的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 441-446.
阅读次数
全文


摘要